drugset
drugset / Trial / NCT06635785

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

NCT06635785 ↗

Phase 1/2 Recruiting 387 enrolled OncoC4, Inc.
NaSequentialOpen-labelTreatment

Summary

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

Timeline

Start
2025-03-26
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AI-081 Monoclonal antibody — Intravenous

Indications

neoplasm